Catalent, Inc. is a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. The company plays a crucial role in the pharmaceutical and biotechnology industries by helping to develop and deliver innovative treatments to patients worldwide.
Catalent's business can be segmented into three main areas:
The company has a strong presence in the United States, with operations in other regions such as Europe, Japan, and China. Catalent's revenue has been steadily increasing, with a reported $5.3 billion in revenue for the fiscal year 2023, an impressive 17% growth compared to the previous year.
Regarding the removal from the S&P 500 in 2024, this could be attributed to various factors, including changes in the index's composition or the company's performance. However, I could not find specific information about this event during my search. It's possible that the removal was part of a routine rebalancing of the index to ensure it remains a representative benchmark of the U.S. stock market.
In conclusion, Catalent is a significant player in the pharmaceutical industry, offering a range of services and technologies that support drug development and delivery. Their expertise in biologics, softgel technologies, and clinical supply services positions them well in the market, as evidenced by their strong financial performance.